GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » ROE % Adjusted to Book Value

WuXi XDC Cayman (HKSE:02268) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman ROE % Adjusted to Book Value?

WuXi XDC Cayman's ROE % for the quarter that ended in Jun. 2023 was 23.07%. WuXi XDC Cayman's PB Ratio for the quarter that ended in Jun. 2023 was N/A. WuXi XDC Cayman's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was N/A.


WuXi XDC Cayman ROE % Adjusted to Book Value Historical Data

The historical data trend for WuXi XDC Cayman's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman ROE % Adjusted to Book Value Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - - 1.27

WuXi XDC Cayman Quarterly Data
Dec20 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial - - - - -

Competitive Comparison of WuXi XDC Cayman's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, WuXi XDC Cayman's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi XDC Cayman's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's ROE % Adjusted to Book Value falls into.



WuXi XDC Cayman ROE % Adjusted to Book Value Calculation

WuXi XDC Cayman's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=8.14% / 6.42
=1.27%

WuXi XDC Cayman's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=23.07% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman (HKSE:02268) Business Description

Comparable Companies
Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (HKSE:02268) Headlines

No Headlines